Impact of neutrophil–lymphocyte ratio, Glasgow Prognostic Score, and postoperative decrease in psoas muscle index on recurrence after curative gastrectomy

Nobuhiro Nakazawa¹, Makoto Sohda¹, Kyoichi Ogata¹, Akihiko Sano², Makoto Sakai¹, Hiromi Ogawa¹, Katsumi Kobayashi³, Kotaro Iwanami³, Michio Maemura², Ken Shirabe¹, and Hiroshi Saeki¹

¹Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ²Department of Surgery, National Hospital Numata hospital, Numata, Gunma, Japan

Abstract: Aim: We investigated whether preoperative or postoperative inflammatory markers and psoas muscle index (PMI), and their change after surgery, could predict postoperative recurrence in gastric cancer (GC).

Methods: Thirty-five patients who underwent curative gastrectomy for pStage II and III GC were retrospectively reviewed. The relationship between preoperative inflammatory markers, Glasgow Prognostic Score (GPS), and PMI, as well as postoperative recurrence, was analyzed presurgery and at 6 months after surgery. Results: In the preoperative data, there was a significant association between postoperative recurrence and high NLR, low total protein, low albumin, low PNI, and high GPS. In the data from 6 months after surgery, there was a significant association between postoperative recurrence and high NLR, high C-reactive protein, and high GPS. The reduction in PMI at 6 months after surgery relative to preoperative data was significantly greater in the cases with recurrence than in those without recurrence. No patients whose PMI increased compared with presurgery had recurrence. Conclusions: The postoperative reduction in PMI at 6 months after surgery relative to presurgery could be a predictive marker of recurrence after curative gastrectomy for patients with pStage II and III GC. J. Med. Invest. 68:119-124, February, 2021

Keywords: Gastric cancer, Recurrence, Psoas muscle index (PMI), Sarcopenia, Systemic inflammatory markers

INTRODUCTION

Gastric cancer (GC) is one of the most common malignancies and is the third-leading cause of malignancy-related death in the world (1). Although the clinical outcome of patients with GC has improved their disease-free status following curative resection and postoperative adjuvant chemotherapy (2), there is still much room for further improvement (3). To develop a perioperative treatment strategy for GC, it is important to identify predictors of its recurrence.

Assessment of prognostic efficacy of systemic inflammatory factors is meaningful to managing patients with GC (4). Several previous reports have revealed that comprehensive systemic inflammatory markers, including the prognostic nutritional index (PNI), Glasgow Prognostic Score (GPS), and neutrophil–lymphocyte ratio (NLR), were independent predictors of survival in patients with GC (4-6). Many reports have only focused on the association between preoperative systemic inflammatory factors and prognoses (7-9). However, systemic inflammatory factors can drastically change after radical surgery for GC, and its association with patients’ prognoses is an unresolved issue (10). From the perspective of cancer recurrence, we considered the importance of postoperative comprehensive systemic inflammatory markers.

Sarcopenia is defined as a reduction in skeletal muscle mass with aging (10), and it is recognized as an important factor in cancer management. In GC, several reports have been published focusing on the association between cancer and sarcopenia (11-15). Many GC studies have focused only on the association between preoperative sarcopenia and postoperative complications and/or prognoses, and the cutoff points, such as psoas muscle index (PMI) and skeletal muscle mass index, have varied from report to report (16-19). Therefore, further research is needed to clarify the clinical significance of sarcopenia in GC.

Although much evidence has been accumulated concerning the significance of inflammatory markers and sarcopenia in patients with GC, few reports have investigated the importance of their evaluation postsurgery or of their change between presurgery and postsurgery. The purpose of this study was to clarify the predictive impact of inflammatory markers and PMI on postoperative recurrence in patients with pStage II and III GC. In this study, we focused on both preoperative and 6 months postoperative data, as well as the difference between presurgery and 6 months after surgery.

PATIENTS AND METHODS

Patients

A total of 35 patients who underwent curative surgery for pStage II and III GC between 2010 and 2014 at the Numata National Hospital Department of Surgery in Numata, Japan, were retrospectively reviewed. The patients with GC were staged according to the Japanese Classification of Gastric Carcinoma (20). Data were collected on patient characteristics, such as age, sex, height, body weight, and body mass index (BMI). In addition, both surgical information (such as surgical methods, lymph node dissection, operative time, and blood loss) and pathological information (such as depth of tumor invasion and lymph node metastasis) were recorded. This study was approved by the institutional review board of Numata National Hospital.
Assessment of systemic inflammatory markers

Results from laboratory tests, such as white blood cell count, NLR, hemoglobin, total protein (TP), albumin, and C-reactive protein (CRP) were collected both before surgery and at 6 months after surgery. The PNI was calculated as $10 \times \text{albumin} + 0.05 \times \text{lymphocyte count}$ (21). The GPS was decided on the basis of CRP and albumin. Patients with elevated CRP ($>0.3 \text{mg/dL}$) and reduced albumin ($<3.5 \text{mg/dL}$) were assigned a score of 2 points. Patients who had either of these two factors were assigned a score of 1 point. Patients who had neither of these factors were assigned a score of 0 points (22).

Assessment of sarcopenia

Computed tomography (CT) was performed in all cases at preoperative staging and at 6 months after surgery as a routine follow-up. The third lumbar vertebra (L3) was chosen as an evaluation point. The PMI was defined as the cross-sectional area of muscle at the L3 level normalized on the basis of patients’ height ($\text{cm}^2/\text{m}^2$). Sarcopenia was defined as a PMI of $<6.0 \text{cm}^2/\text{m}^2$ for men and of $<3.4 \text{cm}^2/\text{m}^2$ for women (23). We also set the value of preoperative PMI at 100% and calculated the percentage at 6 months after surgery relative to preoperative data.

Statistical analysis

Statistically significant differences were analyzed using a Mann–Whitney U test for continuous variables and a chi-squared test for categorical variables. Univariate survival analyses were performed using the Cox proportional hazards model. A probability value of $<0.05$ was considered to be statistically significant. All analyses were performed using JMP Pro 12.0 software (SAS Institute Inc., Cary, NC, USA).

RESULTS

Patient characteristics

Of the 35 patients, 21 were men. Mean age was 70.6 years (range 52.0–90.0 years). Mean BMI was 21.1 (range 14.3–24.8 $\text{kg/m}^2$). Of the 35 patients, the depth of tumor invasion was deeper than the subserosa in 32 patients, and 30 patients had lymph node metastasis. There were eight patients with pStage II (22.9%) and 27 patients with pStage III (77.1%). No patients had recurrence within 6 months after surgery. The surgical methods were distal gastrectomy in 21 (60.0%) patients and total gastrectomy (TG) in 14 (40.0%) patients. Regarding the postoperative complications, there were no patients with higher than grade 3 Clavien–Dindo classification. During the study period, S-1 was administered to 28 (80%) patients as postoperative adjuvant chemotherapy. The reasons for absence of postoperative adjuvant chemotherapy in the remaining 7 (20%) patients were advanced age, poor performance status, comorbid conditions, or an inability to obtain consent.

Association between patients’ clinical data and postoperative recurrence

Recurrence was observed in 15 (42.9%) of 35 patients. The association between recurrence and clinicopathological features in the 35 patients with GC is shown in Table 1. There were significant associations between recurrence and the presence of lymph node metastasis ($p = 0.013$) and advanced pathological stage ($p = 0.036$). In contrast, there was no significant association in terms of age, sex, BMI, depth of tumor invasion, operative method, lymph node dissection, blood loss, or administration of adjuvant chemotherapy with S-1.

Systemic inflammatory factors and PMI at presurgery and 6 months after surgery with regard to recurrence

In the preoperative evaluation, there was a significant relationship between postoperative recurrence and high NLR ($p = 0.011$), low TP ($p = 0.025$), and low albumin ($p = 0.0077$), as shown in Table 2. Regarding PNI and GPS, many recurrences were found in the cases with low PNI ($p = 0.0041$) and high GPS ($p = 0.0011$).

In terms of 6 months after surgery, there was a significant relationship between recurrence and high NLR ($p = 0.013$) and high CRP ($p = 0.040$). Regarding PNI and GPS, we found that GPS was significantly associated with recurrence ($p = 0.046$), whereas PNI was not.

There was no significant correlation between PMI and recurrence for either presurgery or 6 months after surgery.

Changes in systemic inflammatory factors and PMI at presurgery and 6 months after surgery with regard to recurrence

The decrease in PMI at 6 months after surgery relative to preoperative data was significantly greater in the cases with recurrence than those without recurrence ($96.8 \pm 3.7\%$ vs. $82.0 \pm 4.3\%$, $p = 0.014$), whereas no significant correlations were found in NLR, PNI, or GPS, as shown in Table 3.

Association between patients’ clinical data and the changes in PMI

Reductions in PMI were observed in 28 (80%) of 35 patients. The association between changes in PMI and clinicopathological features in 35 patients with GC is shown in Table 4. There

---

**Table 1.** The relationship between clinicopathological features and postoperative recurrence in 35 GC patients.

| Factors                  | Recurrence |
|--------------------------|------------|
|                          | Absent     | Present    | $p$ value |
|                          | n = 20     | n = 15     |            |
| Age (years)              | 68.1 ± 2.0 | 73.9 ± 2.3 | 0.07       |
| Gender                   |            |            |            |
| Male                     | 12         | 9          | 1.00       |
| Female                   | 8          | 6          |            |
| BMI (kg/m²)              | 20.5 ± 0.6 | 21.8 ± 0.6 | 0.15       |
| Depth                    |            |            |            |
| M, SM, MP                | 3          | 0          | 0.06       |
| SS, SE, SI               | 17         | 15         |            |
| Lymph node metastasis    |            |            |            |
| Absent                   | 5          | 0          | 0.013*     |
| Present                  | 15         | 15         |            |
| Stage                    |            |            |            |
| II                       | 7          | 1          | 0.036*     |
| III                      | 13         | 14         |            |
| Operative method         |            |            |            |
| Distal gastrectomy       | 13         | 8          | 0.49       |
| Total gastrectomy        | 7          | 7          |            |
| Lymph node dissection    |            |            |            |
| D1, D1+                  | 6          | 8          | 0.18       |
| D2                       | 12         | 6          |            |
| Operative time (min)     | 329.1 ± 19.7 | 377.7 ± 25.3 | 0.14       |
| Blood loss (ml)          | 393.6 ± 82.2 | 542.5 ± 105.2 | 0.27       |
| Adjuvant chemotherapy    |            |            |            |
| Not-performed            | 3          | 4          | 0.4        |
| Performed                | 17         | 11         |            |
### Table 2. PMI and systemic inflammatory factors at the point of before operation and 6 months after operation with regard to recurrence.

| Factors                      | Before operation | P value | 6 months after operation | P value |
|------------------------------|------------------|---------|--------------------------|---------|
|                              | Absent (n = 20)  | Present (n = 15) |                       |         |
| White Blood Cell (WBC) (mm³) |                  |          |                          |         |
|                              | 5873.5 ± 407.5   | 6596.0 ± 470.6 | 0.25                    |         |
|                              |                  | 4211.5 ± 372.1 | 5340.7 ± 429.7          | 0.055   |
| NLR                          | 2.2 ± 0.3        | 3.6 ± 0.4 | 0.011*                  | 1.2 ± 0.2 | 2.0 ± 0.2 | 0.013* |
| Hemoglobin (g/dl)            |                  |          |                          |         |
|                              | 12.4 ± 0.6       | 11.1 ± 0.7 | 0.16                    |         |
|                              |                  | 11.8 ± 0.4 | 11.4 ± 0.7              | 0.57    |
| Total Protein (g/dl)         |                  |          |                          |         |
|                              | 7.0 ± 0.2        | 6.3 ± 0.2 | 0.025                   |         |
|                              |                  | 7.0 ± 0.1 | 6.8 ± 0.2               | 0.22    |
| Albumin (g/dl)               |                  |          |                          |         |
|                              | 4.3 ± 0.1        | 3.7 ± 0.2 | 0.0077*                 |         |
|                              |                  | 4.4 ± 0.1 | 4.1 ± 0.11              | 0.12    |
| C-reactive Protein (mg/dl)   |                  |          |                          |         |
|                              | 0.06 ± 0.2       | 0.7 ± 0.2 | 0.050                   |         |
|                              |                  | 0.05 ± 0.08 | 0.3 ± 0.09          | 0.040*  |
| PNI Score                    | 51.1 ± 1.6       | 43.7 ± 1.8 | 0.0041*                 | 52.4 ± 1.5 | 50.0 ± 1.8 | 0.31   |
| GPS Score                    | 0.0 ± 0.1        | 0.7 ± 0.1 | 0.0011*                 | 0.0 ± 0.1 | 0.3 ± 0.1  | 0.046*  |
| PMI Score                    | 4.2 ± 0.3        | 3.9 ± 0.4 | 0.52                    |         |
| Sarcopenia (Using PMI cut-off point) |       |          |                          |         |
| Non-sarcopenia               | 6               | 3       | 0.50                    |         |
| Sarcopenia                   | 14              | 12      | 3                       |         |
|                              |                  |          | 0                       |         |
|                              |                  |          | 0.06                    |         |

* NLR Neutrophil-to-Lymphocyte Ratio, PNI Prognostic Nutritional Index, GPS Glasgow Prognostic Score, PMI cut-off point 6.0 cm²/m² (men) and 3.4 cm²/m² (women)

### Table 3. Changes of PMI and systemic inflammatory factors from before operation to 6 months after operation with regard to recurrence.

| Factors                      | Before operation | P value | 6 months after operation | P value |
|------------------------------|------------------|---------|--------------------------|---------|
|                              | Absent (n = 20)  | Present (n = 15) |                       |         |
| White Blood Cell (WBC) (mm³) |                  |          |                          |         |
|                              | 5873.5 ± 407.5   | 6596.0 ± 470.6 | 0.25                    |         |
|                              | 4211.5 ± 372.1   | 5340.7 ± 429.7 | 0.055                   |         |
| NLR                          | 2.2 ± 0.3        | 3.6 ± 0.4 | 0.011*                  | 1.2 ± 0.2 | 2.0 ± 0.2 | 0.013* |
| Hemoglobin (g/dl)            |                  |          |                          |         |
|                              | 12.4 ± 0.6       | 11.1 ± 0.7 | 0.16                    |         |
|                              | 11.8 ± 0.4       | 11.4 ± 0.7 | 0.57                    |         |
| Total Protein (g/dl)         |                  |          |                          |         |
|                              | 7.0 ± 0.2        | 6.3 ± 0.2 | 0.025                   |         |
|                              | 7.0 ± 0.1        | 6.8 ± 0.2 | 0.22                    |         |
| Albumin (g/dl)               |                  |          |                          |         |
|                              | 4.3 ± 0.1        | 3.7 ± 0.2 | 0.0077*                 |         |
|                              | 4.4 ± 0.1        | 4.1 ± 0.11 | 0.12                    |         |
| C-reactive Protein (mg/dl)   |                  |          |                          |         |
|                              | 0.06 ± 0.2       | 0.7 ± 0.2 | 0.050                   |         |
|                              | 0.05 ± 0.08      | 0.3 ± 0.09 | 0.040*                 |         |
| PNI Score                    | 51.1 ± 1.6       | 43.7 ± 1.8 | 0.0041*                 | 52.4 ± 1.5 | 50.0 ± 1.8 | 0.31   |
| GPS Score                    | 0.0 ± 0.1        | 0.7 ± 0.1 | 0.0011*                 | 0.0 ± 0.1 | 0.3 ± 0.1  | 0.046*  |
| PMI Score                    | 4.2 ± 0.3        | 3.9 ± 0.4 | 0.52                    |         |
| Sarcopenia (Using PMI cut-off point) |       |          |                          |         |
| Non-sarcopenia               | 6               | 3       | 0.50                    |         |
| Sarcopenia                   | 14              | 12      | 3                       |         |

* NLR Neutrophil-to-Lymphocyte Ratio, PNI Prognostic Nutritional Index, GPS Glasgow Prognostic Score, PMI cut-off point 6.0 cm²/m² (men) and 3.4 cm²/m² (women)

### Table 4. The relationship between clinicopathological features and PMI decrease or increase compared to before operation.

| Factors                      | PMI Decrease | Increase | P value |
|------------------------------|--------------|----------|---------|
|                              | n = 28       | n = 7    |         |
| Age (years)                  | 70.6 ± 1.8   | 70.3 ± 3.6 | 0.93    |
| Gender                       |              |          |         |
| Male                         | 17           | 4        | 0.86    |
| Female                       | 11           | 3        |         |
| BMI (kg/m²)                  | 21.1 ± 0.5   | 21.1 ± 1.0 | 0.94    |
| Depth                        |              |          |         |
| M, SM, MP                    | 3            | 0        | 0.55    |
| SS, SE, SI                   | 25           | 7        |         |
| Lymph node metastasis        |              |          |         |
| Absent                       | 2            | 3        | 0.030*  |
| Present                      | 26           | 4        |         |
| Stage                        |              |          |         |
| I                            | 7            | 1        | 0.53    |
| II                           | 21           | 6        |         |
| Operative method             |              |          |         |
| Distal gastrectomy           | 16           | 5        | 0.48    |
| Total gastrectomy            | 12           | 2        |         |
| Adjuvant chemotherapy        |              |          |         |
| Not-performed                | 5            | 2        | 0.54    |
| Performed                    | 23           | 5        |         |
| Recurrence                   |              |          |         |
| Absent                       | 13           | 7        | 0.0025*  |
| Present                      | 15           | 0        |         |
were significant associations between reduced PMI and the presence of lymph node metastasis \( (p = 0.030) \) and postoperative recurrence \( (p = 0.0025) \). All the patients with increased PMI compared with presurgery had no recurrence.

**Association between systemic inflammatory factors and changes in PMI**

Patients with increased PMI had significantly lower preoperative NLR \( (p = 0.040) \), as shown in Table 5. However, no significant correlation was observed at months after surgery in patients with increased PMI.

**DISCUSSION**

In this study, we analyzed systemic inflammatory markers and PMI at presurgery and at 6 months after surgery in patients with GC with pStage II and III in terms of postoperative recurrence. There was significant association between postoperative recurrence and high NLR, low TP, low PNI, and high GPS in the preoperative evaluation, whereas high NLR, high CRP, and high GPS were shown in the data for postoperative recurrence at 6 months after surgery. There were significant associations between postoperative reductions in PMI and the presence of lymph node metastasis and postoperative recurrence. Furthermore, no cases with postoperative increase of PMI had recurrence. Our results suggest that sarcopenia and inflammatory markers should be evaluated at multiple points peri-operation because they are changeable depending on patients’ background factors.

NLR is reported to be strongly associated with sarcopenia \((24)\). In our research, it was useful to predict recurrence both preoperatively and at 6 months after surgery. PNI and GPS are also known as significant predictors of the prognosis in GC \((4)\); however, the effectiveness of evaluation at 6 months after surgery is poorly understood. Regarding PNI and GPS, we found that GPS was significantly associated with recurrence \( (p = 0.046) \) at 6 months after surgery, whereas PNI was not. The following two reasons were considered: First, TP and albumin tended to improve after surgery, which could have influenced PNI. Second, CRP had an association with recurrence at 6 months after surgery, affecting the positive correlation between GPS and recurrence. We should note the change in NLR and CRP in order to predict recurrence at 6 months after surgery.

Previous studies have focused on the effect of sarcopenia on GC outcomes \((13, 25, 26)\). However, there were variations in the sarcopenia evaluation point, cutoff point, patient’s background, and study design in each paper. To clarify whether PMI and systemic inflammatory markers had a relationship with recurrence, we focused on patients with pStage II or III GC in this study. In this study, 24 (68.6%) patients were older than 65 years. As mentioned earlier, sarcopenia was defined as a PMI of <6.0 cm\(^2\)/m\(^2\) for men and <3.4 cm\(^2\)/m\(^2\) for women \((23)\). When we adopted these cutoff points, 26 (74.3%) patients and 32 (91.4%) patients were defined as having sarcopenia presurgery and at 6 months after surgery, respectively. We did not find a significant association between recurrence and sarcopenia while employing the cutoff point of PMI. Kiyama T et al. had shown a significant loss of body protein of 8% at 6 months after TG \((27)\). Yamaoka Y et al. had also found that approximately 25% of patients showed a significant loss of skeletal muscle of >10% at 1 year after TG \((28)\). Therefore, we set the value of preoperative PMI as 100%.

| Factors                          | Before operation |       |       | 6 months after operation |       |       |
|--------------------------------|-----------------|-------|-------|--------------------------|-------|-------|
|                                | PMI             |       |       |                          |       |       |
|                                | Decrease (n = 28) | Increase (n = 7) |       | PMI                      | Decrease (n = 28) | Increase (n = 7) |       |
| White Blood Cell (WBC) mm\(^3\) | 6360.7 ± 344.5  | 5472.9 ± 689.1 | 0.26 | 4763.6 ± 331.7  | 4422.9 ± 663.4 | 0.65 |
| NLR                            | 3.0 ± 0.3       | 1.6 ± 0.6       | 0.040* | 1.6 ± 0.2    | 1.2 ± 0.4      | 0.4  |
| Hemoglobin g/dl                 | 11.9 ± 0.5      | 11.7 ± 1.0      | 0.90  | 11.7 ± 0.4    | 11.6 ± 0.7      | 0.94 |
| Total Protein g/dl              | 6.7 ± 0.2       | 6.7 ± 0.3       | 0.91  | 6.9 ± 0.1    | 7.2 ± 0.2      | 0.22 |
| Albumin g/dl                    | 4.0 ± 0.1       | 4.1 ± 0.2       | 0.85  | 4.2 ± 0.1    | 4.4 ± 0.2      | 0.25 |
| C-reactive protein mg/dl        | 0.39 ± 0.2      | 0.05 ± 0.3      | 0.38  | 0.19 ± 0.07  | 0.04 ± 0.1      | 0.34 |
| PNI score                       | 47.4 ± 1.5      | 49.9 ± 3.0      | 0.45  | 51.2 ± 1.3   | 52.1 ± 2.6      | 0.77 |
| GPS score                       | 0.4 ± 0.1       | 0.0 ± 0.2       | 0.17  | 0.2 ± 0.1    | 0.0 ± 0.2      | 0.40 |
| PMI score                       | 4.1 ± 0.3       | 4.1 ± 0.5       | 0.94  | 3.4 ± 0.3    | 5.2 ± 0.7      | 0.023*|
| Sarcopenia (Using PMI cut-off point) |       |       |       |                          |       |       |
| Non-sarcopenia                  | 6              | 3      | 0.26  | 0              | 3      | 0.0010*|
| Sarcopenia                      | 22             | 4      | 28    | 4              |       |       |
and calculated the percentage at 6 months after surgery relative to preoperative data. We found that PMI was significantly lower at 6 months after surgery in cases with recurrence (96.8 ± 3.7% vs. 82.0 ± 4.3%). The receiver operating characteristic curve constructed to investigate the association between the transition of PMI and recurrence demonstrated that the cutoff point was 93.0%. This cutoff meant that cases with a PMI reduction of >7% had a relative risk of recurrence. In this way, preventing the loss of PMI after surgery could lead to improved patient outcomes. Furthermore, focusing on the transition of PMI is valuable because it is independent of the patient’s age. Given sarcopenia and GC prognoses are related, early nutritional status assessments are useful (26, 29). Proinflammatory cytokines, including interleukin (IL)-1, IL-6, and tumor necrosis factor-α, were found to be mediators of skeletal muscle proteolysis loss and are the components of sarcopenia (30). Okumura S et al. suggested that decreasing muscle mass should give rise fewer cytokines which causes decreased immunity (31). Lutz CT et al. also reported that decreased cytokine levels suppress the function of natural killer cells in sarcopenia (32). Evaluation of these proinflammatory cytokines after surgery might be meaningful.

Our study has some limitations. It had a small sample size, which could bias the results. Further large-scale clinical trials are needed to clarify the potential of the transition of PMI as a new predictive biomarker for GC recurrence. Also, the diagnosis of sarcopenia requires measurement of walking speed and grip strength (33, 34), but it is difficult to evaluate in those with poor physical condition and in the elderly. We focused on CT, which is frequently used in GC management. The significance of walking speed and grip strength to evaluate postoperative change of sarcopenia could be further investigated.

In conclusion, the transition of PMI was significantly correlated with recurrence in pStage II and III patients with GC. Furthermore, evaluating systemic inflammatory factors, such as NLR, PMI, and GPS, was also considered important. NLR and GPS were useful predictive markers both preoperatively and at 6 months after surgery. In particular, the change in PMI at 6 months after surgery compared with presurgery was a useful prognostic predictor. Given CT is performed for preoperative staging and postoperative follow-up in almost all cases of GC, the findings can be used to identify changes in skeletal muscle and provide nutritional assessment, which could improve clinical outcomes.

CONFLICT OF INTERESTS

We have no conflicts of interest to declare.

ETHICAL APPROVAL

All research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The data request and study protocol were approved by the institutional review board of Numata National Hospital.

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65(2): 87-108, 2015
2. Yamashita K, Sakuramoto S, Nemoto M, Shibata T, Miendo H, Katada N, Kikuchi S, Watanabe M: Trend in gastric cancer : 35 years of surgical experience in Japan. World J Gastroenterol 17(29): 3390-3397, 2011
3. Cao J, Qi F, Liu T: Adjuvant chemotherapy after curative resection for gastric cancer : a meta-analysis. Scand J Gastroenterol 49(6): 690-704, 2014
4. Li QQ, Lu ZH, Yang L, Lu M, Zhang XT, Li J, Zhou J, Wang XG, Gong JP, Gao J, Li J, Li Y, Shen L: Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pac J Cancer Prev 15(2): 945-950, 2014
5. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, Faulis AK, Horgan PG, McMillan DC: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47(17): 2633-2641, 2011
6. Jeong JH, Lim SM, Yun JY, Rhee GW, Lim JY, Cho JY, Kim YR: Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology 83(5): 292-299, 2012
7. Kuroda D, Sawayama H, Kurashige J, Ikawatsuki M, Eto T, Tokunaga R, Kitano Y, Yamamura K, Ouchi M, Nakamura K, Baba Y, Sakamoto Y, Yamashita Y, Yoshida N, Chikamoto A, Baba H: Controlling nutritional status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. Gastric Cancer 21: 204-212, 2017
8. Takagi K, Yagi T, Umeda Y, Shinoura S, Yoshida R, Nobuoka D, Kuise T, Araki H, Fujiwara T: Preoperative controlling nutritional status (CONUT) score for assessment of prognosis following hepatocarcinoma for hepatocellular carcinoma. World J Surg 41(9): 2353-2360, 2017
9. Toyokawa T, Kubo N, Tamura T, Sakurai K, Amano R, Tanaka H, Muguruma K, Yashiro M, Hirakawa K, Ohira M: The pretreatment controlling nutritional status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. BMC Cancer 16: 722, 2016
10. Rosenberg IH: Sarcopenia: Origins and clinical relevance. Clin Geriatr Med 27(3): 337-339, 2011
11. McClearay NJ, Dotan E, Browner I: Refining the chemotherapy approach for older patients with colon cancer. J Clin Oncol 32(24): 2570-2580, 2014
12. Robinson TN, Eiseman B, Wallace JD, Church SD, McFann KK, Pfister SM, Sharp TJ, Moss M: Redefining geriatric preoperative assessment using frailty, disability and comorbidity. Ann Surg 250(3): 449-455, 2009
13. Huang CL, Shen X, Huang YY, Zhang FM, Chen XY, Ma LL, Chen XL, Yu Z, Wang SL: Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: A propensity score-matched analysis from a large-scale cohort. Surgery 166(3): 297-304, 2019
14. Zhang CL, Shen X, Huang YY, Zhang FM, Chen XY, Ma LL, Chen XL, Yu Z, Wang SL: Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: A propensity score-matched analysis from a large-scale cohort. Surgery 166(3): 297-304, 2019
15. Kwada K, Kuroda S, Kikuchi S, Yoshida R, Nishizaki M, Kagawa S, Fujiwara T: Clinical impact of sarcopenia on gastric cancer. Anticancer Res 39(5): 2241-2249, 2019
16. Hu CL, Jin XH, Yuan ZD, Xiong SW, Zhang L, Hou JN, Ao S, Wu JL, Shi HP, Ji JF, Lyv GQ: Prognostic significance of preoperative skeletal muscle status in patients with gastric cancer after radical gastrectomy. Asia Pac J Clin Nutr 28(3): 442-449, 2019
17. Sakurai K, Kubo N, Tamura T, Toyokawa T, Amano R, Tanaka H, Muguruma K, Yashiro M, Maeda K, Hirakawa
K, Ohira M: Adverse effects of low preoperative skeletal muscle mass in patients undergoing gastrectomy for gastric cancer. Ann Surg Oncol 24: 2712-2719, 2017
18. Zheng ZF, Lu J, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Zheng CH, Huang CM, Li P: Preoperative skeletal muscle index vs the controlling nutritional status score: Which is a better objective predictor of long-term survival for gastric cancer patients after radical gastrectomy? Cancer Med 7(8): 3537-3547, 2018
19. Zheng ZF, Lu J, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Chen QY, Lin M, Huang CM: A novel prognostic scoring system based on preoperative sarcopenia predicts the long-term outcome for patients after R0 resection for gastric cancer: experiences of a high-volume center. Ann Surg Oncol 7: 1795-1803, 2017
20. Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14(2): 101-112, 2011
21. Onodera T, Goseki N, Kosaki G: Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 85(9): 1001-1005, 1984
22. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O’Reilly DS, Fouliis AK, Horgan PG, McMillan DC: An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A Glasgow inflammation outcome study. Br J Cancer 104(4): 726-734, 2011
23. Durand F, Bayse S, Francoz C, Laouénan C, Bruno O, Belghiti J, Moreau R, Vilgrain V, Valla D: Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 60(6): 1151-1157, 2014
24. Lin J, Zhang W, Huang Y, Chen W, Wu R, Chen X, Lou N, Wang P: Sarcopenia is associated with the neutrophil/lymphocyte and platelet/lymphocyte ratios in operable gastric cancer patients: a prospective study. Cancer Manag Res 10: 4935-4944, 2018
25. Fukuda Y, Yamamoto K, Hirao M, Nishikawa K, Nagatsuka Y, Nakayama T, Tanikawa S, Maeda S, Uemura M, Miyake M, Hama N, Miyamoto A, Ikeda M, Nakamori S, Sekimoto M, Fujitani K, Tsujinaka T: Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. Gastric Cancer 19(3): 986-993, 2016
26. Wang SL, Huang DD, Pang WY, Lou N, Chen FF, Zhou CJ, Shen X, Yu Z: Sarcopenia adversely impacts postoperative clinical outcomes following gastrectomy in patients with gastric cancer: A prospective study. Ann Surg Oncol 23(2): 556-564, 2016
27. Kiyama T, Mizutani T, Okuda T, Fujita I, Tokunaga A, Tajiri T, Barbui A: Postoperative changes in body composition after gastrectomy. J Gastrointest Surg 9(3): 313-319, 2005
28. Yamaoka Y, Fujitani K, Tsujinaka T, Yamamoto K, Hirao M, Sekimoto M: Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy. Gastric Cancer 18(2): 382-389, 2015
29. Zhuang CL, Huang DD, Pang WY, Zhou CJ, Wang SL, Lou N, Ma LL, Yu Z, Shen X: Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort. Medicine (Baltimore) 95(13): e3164, 2016
30. Argilés JM, Busquets S, López-Soriano FJ: The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol 37(8): 1609-1619, 2005
31. Okumura S, Kako T, Hamaguchi Y, Fujimoto Y, Kobayashi A, Iida T, Yagi S, Taura K, Hatanou E, Uemoto S: Impact of the preoperative quantity and quality of skeletal muscle on outcomes after resection of extrahepatic biliary malignancies. Surgery 159(3): 821-833, 2016
32. Charles TL, LeBris SQ: Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging (Albany NY) 4(8): 535-546, 2012
33. Cruz-Jentoft AJ, Landi F, Schneider SM, Zúñiga C, Arai H, Bour H, Chen LK, Fielding RA, Martin FC, Michel JP, Sieber C, Stout JR, Studenski SA, Vellas B, Woo J, Zamboni M, Cederholm T: Prevalence of and Interventions for Sarcopenia in Ageing Adults: A Systematic Review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 43(6): 748-759, 2014
34. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, Lee JSW, Lee WJ, Lee Y, Liang CK, Limppawattana P, Lin CS, Peng LN, Satake S, Suzuki T, Wan CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H: Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15(2): 95-101, 2014